Un groupe basé sur la complémentarité d'expertise avec un savoir-faire pluridisciplinaire

Une gamme de solutions intégrées en biotechnologie

Actualité

QVQ joins the Biotech Investissement Group

Date de publication : 12/10/2018

Dear Customers and Partners

We are pleased to announce that QVQ, a company based in Utrecht (The Netherlands), is now a sister company of RD-Biotech SAS, Diaclone SAS and SynAbs SA (Biotech Investissement Group – www.mabexperts.com).

QVQ has strong expertise in the development and production of single domain antibodies derived from llamas, which are referred to as VHHs. VHHs have unique biochemical properties due to their small size and high stability which make them very useful for tumour targeting particularly in imaging technologies and companion diagnostics. QVQ offers multiple services related to development, reformatting and optimization of VHHs with respect to stability, production levels and humanization. Besides contract research and services, QVQ has developed a growing portfolio of proprietary detection/imaging VHHs directed against targets in disease related with oncology, age disease and infectious diseases.

By joining the Biotech Investissement group, QVQ will complement the high level of expertise already present within the group, to develop and market new high-quality diagnostic assays and imaging products.

Please do not hesitate to get in touch if you require information about the QVQ products and services.

Yours faithfully

 Philippe Dulieu, CEO

Contact:

Phone +33(0)3 81 53 88 37 – Mail : info@mabexperts.com

  • CAM FAMILY
    The CAM family: A new target for monitoring or treating cancers?
    Date de publication : 21/05/2019

    The cell adhesion molecules (CAMs) family includes more than 50 proteins with four main groups: immunoglobulin (Ig)-like CAMs, cadherins, selectins, and integrins.

    Diaclone has been interested for...

    Plus d'info
  • FAST ELISA
    Venez découvrir et testez les kits fastELISA de RD-Biotech
    Date de publication : 21/05/2019

    Venez découvrir et testez les kits fastELISA de RD-Biotech : Les kits ELISA les plus rapides du marché !

    1 seule étape d’incubation – Résultats en...

    Plus d'info
  • PSL
    PSL Alliance
    Date de publication : 18/05/2019

    Diaclone is a core member of the PSL Alliance, a network of biotech companies gathered by UK-based company Pivotal Scientific...

    Plus d'info
  • EuSARC 2019
    EuSARC 2019
    Date de publication : 07/05/2019

    Diaclone  is pleased to be sponsor of the EuSARC congress, taking place on May 30th-June 1st in Benediktbeuern, Germany. Don't hesitate to contact our Area sales manager, Norbert Gregor, in...

    Plus d'info
  • AIS LOGO
    7ème Antibody Industrial Symposium 2019
    Date de publication : 23/04/2019



    Diaclone et le groupe mAbexperts seront présents au 7ème Antibody Industrial Symposium 2019 (AIS 2019)  “Harnessing the immune system with therapeutic antibodies”...

    Plus d'info
  • IL-17
    DIACLONE Assays for the Human IL-17 Family
    Date de publication : 23/04/2019

    DIACLONE has developed one of the largest ranges of ELISA and ELISpot kits available for the detection of Human IL-17A, IL-17F and IL-17A/F:




    Human IL-17A ELISpot...

    Plus d'info
  • Prod cell
    NOUVEAU ! RD-Biotech fournisseur de l’anticorps monoclonal murin D1-25, pour la quantification par ELISA de la glycoprotéine G du virus de la rage.
    Date de publication : 08/04/2019

    Signature d’un accord de licence avec Institut Pasteur France permettant à RD-Biotech de commercialiser l’anticorps monoclonal murin D1-25  (anti-glycoprotéine G du...

    Plus d'info
  • QVQ joins the Biotech Investissement Group
    Date de publication : 12/10/2018

    Dear Customers and Partners

    We are pleased to announce that QVQ, a company based in Utrecht (The Netherlands), is now a sister company of RD-Biotech SAS, Diaclone SAS and SynAbs SA (Biotech...

    Plus d'info
  • Diaclone est partenaire d’un projet européen d’envergure associant une douzaine de partenaires de la région de Besançon
    Date de publication : 21/08/2018

    Le Projet MiMédi

    MIMEDI: MIcrotechnique pour les MEDicaments Innovants nouvelles solutions technologiques pour optimiser la fabrication de "cellules médicaments"

    Au sein...

    Plus d'info